Skip to main content

Table 3 Results of network meta-analysis (data under the cells marked with italic drugs) and direct comparison (data above the cells marked with italic drugs) of all treatments

From: Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis

Placebo

     

− 0.05 (− 0.36, 0.27) [27, 29]

  

0.14 (− 0.26, 0.54)

Glyburide

− 0.95 (− 1.29, − 0.61) [14, 32]

  

0.07 (− 0.11, 0.24) [31]

0.09 (− 0.19, 0.36) [33]

  

1.09 (0.57, 1.62)

0.95 (0.61, 1.29)

Gliclazide

      

0.12 (− 0.72, 0.96)

− 0.02 (− 0.76, 0.73)

− 0.97 (− 1.79, − 0.15)

Voglibose

   

− 0.20 (− 0.65, 0.25) [18]

 

0.13 (− 0.50, 0.76)

− 0.01 (− 0.50, 0.49)

− 0.96 (− 1.56, − 0.36)

0.01 (− 0.85, 0.87)

Metformin

0.05 (− 0.41, 0.52) [19]

   

0.08 (− 0.35, 0.50)

− 0.06 (− 0.23, 0.10)

− 1.02 (− 1.40, − 0.64)

− 0.05 (− 0.77, 0.68)

− 0.05 (− 0.52, 0.41)

Pioglitazone

0.06 (− 0.56, 0.68) [30]

 

− 0.06 (− 0.49, 0.38) [28]

0.05 (− 0.27, 0.36)

− 0.10 (− 0.35, 0.16)

− 1.05 (− 1.47, − 0.62)

− 0.08 (− 0.86, 0.70)

− − 0.09 (− 0.63, 0.46)

− 0.03 (− 0.32, 0.26)

Rosiglitazone

  

0.32 (− 0.39, 1.03)

0.18 (− 0.41, 0.77)

− 0.77 (− 1.46, − 0.09)

0.20 (− 0.25, 0.65)

0.19 (− 0.55, 0.92)

0.24 (− 0.33, 0.81)

0.27 (− 0.36, 0.91)

Sitagliptin

0.18 (− 0.18, 0.55) [17]

0.14 (− 0.47, 0.74)

− 0.01 (− 0.47, 0.46)

− 0.96 (− 1.54, − 0.38)

0.01 (− 0.57, 0.59)

0.00 (− 0.63, 0.64)

0.06 (− 0.38, 0.49)

0.09 (− 0.43, 0.61)

− 0.18 (− 0.55, 0.18)

Conventional